Open letter to the Executive Director of the European Medicines Agency concerning the licensing of hydroxyethyl starch solutions for fluid resuscitation

British Journal of Anaesthesia

Volumn 112, Issue 3, 2014, Pages 595-600

  Bellomo, R ^a   Bion, J ^a   Finfer, S ^a   Myburgh, J ^a   Perner, A ^a   Reinhart, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH;

BLEEDING; BLOOD CLOTTING DISORDER; BURN; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FLUID RESUSCITATION; HUMAN; HYPOVOLEMIA; KIDNEY FUNCTION; KIDNEY INJURY; LETTER; LICENSING; MORTALITY; PATIENT SAFETY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SEPSIS; SURVIVAL RATE; TISSUE PRESERVATION;

EUROPE; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; LICENSURE; PHARMACEUTICAL SOLUTIONS; PHARMACOVIGILANCE; PLASMA SUBSTITUTES; PRODUCT RECALLS AND WITHDRAWALS; RESUSCITATION;

EID: 84896897657     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu025     Document Type: Letter

References (25)

1. European Medicines Agency (EMA). PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients. Press Release. 2013. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/10/ news-detail-001917.jsp&mid=WC0b01ac058004d5c1
2. European Medicines Agency (EMA). PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. Press Release. 2013. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news-and-events/news/2013/06/news-detail-001814.jsp&mid=WC0b01ac058004d5c1
3. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620-2
4. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39
5. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0. 42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367: 124-34
6. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethyl-starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 911-6
7. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901-11
8. Bellmann R, Feistritzer C, Wiedermann CJ. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clin Pharmacokinet 2012; 51: 225-36
9. Auwerda JJ, Wilson JH, Sonneveld P. Foamymacrophagesyndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. Ann Intern Med 2002; 137: 1013-4
10. Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M. Hydrops lysosomalis generalisatus-an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006; 77: 83-5
11. Ginz HF, Gottschall V, Schwarzkopf G, Walter K. Excessive tissue storage of colloids in the reticuloendothelial system. Anaesthesist 1998; 47: 330-4
12. Stander S, Richter L, Osada N, Metze D. Hydroxyethylstarch-induced pruritus: clinical characteristics and influence of dose, molecular weight and substitution. Acta Derm Venereol 2013, doi:0. 2340/00015555-1639
13. Jonville-Bera AP, Autret-Leca E, Gruel Y. Acquired type I von Willeb-rand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001; 345: 622-3
14. Alexander B, Odake K, Lawlor D, Swanger M. Coagulation, hemosta-sis, and plasma expanders: a quarter century enigma. Fed Proc 1975; 34: 1429-40
15. Sossdorf M, Marx S, Schaarschmidt B, et al. HES 130/0. 4 impairs haemostasisandstimulatespro-inflammatorybloodplateletfunc-tion. Crit Care 2009; 13: R208
16. Haase N, Wetterslev J, Winkel P, Perner A. Bleeding and riskofdeath with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med 2013, doi:10. 1007/s00134-013-3111-9
17. Hecht-Dolnik M, Barkan H, Taharka A, Loftus J. Hetastarch increases the riskof bleeding complicationsinpatients after off-pump coronary bypass surgery: a randomized clinical trial. J Thorac Cardiovasc Surg 2009; 138: 703-11
18. Mittermayr M, Streif W, Haas T, et al. Hemostatic changes aftercrys-talloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007; 105: 905-17
19. Rasmussen KC, Johansson PI, Hojskov M, et al. Hydroxyethyl starch reduces coagulation competence and increases blood loss during major surgery: results from a randomized controlled trial. Ann Surg 2013, doi:10. 1097/SLA. 0000000000000267
20. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitationwith hydroxyethylstarchimprovesrenalfunctionand lactate clearanceinpenetratingtraumainarandomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth 2011; 107: 693-702
21. Haynes GR, Havidich JE, Payne KJ. Why the Food and Drug Adminis-tration changed the warning label for hetastarch. Anesthesiology 2004; 101: 560-1
22. Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2013; 7: CD007594
23. Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. J Am Med Assoc 2013;309: 678-88
24. Annane D, Siami S, Jaber S, et al. for the CRISTAL Investigators. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. J Am Med Assoc 2013, doi:10. 1001/jama. 2013. 280502
25. Seymour CW, Angus DC. Makinga pragmatic choice for fluid resuscitation in critically ill patients. J Am Med Assoc 2013, doi:10. 1001/jama. 2013. 280503